Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.
A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the ...
HHS Secretary Robert F. Kennedy Jr. has claimed without scientific basis that SSRIs are as addictive as heroin and linked ...
“Abrupt” reductions in antidepressant treatment “ranging from 20 percent to 50 percent” Increases in psychotropic drug ...
The FDA has recommended several labeling changes to all approved testosterone replacement therapy products based on the ...
WASHINGTON (AP) — U.S. health officials are tracking a rise in injuries tied to the misuse of nitrous oxide, or laughing gas, ...
For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...
Lipocine announces US FDA labelling changes for testosterone products: Salt Lake City Thursday, March 13, 2025, 16:00 Hrs [IST] Lipocine Inc., a biopharmaceutical company leveragi ...
The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.
The FDA has announced new labeling changes for all testosterone products following a review of clinical trial data, including a TRAVERSE study and postmarket ambulatory blood pressure studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback